|
Daily Medical Update
Lung Cancer
Tuesday, September 01, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of clinical nursing (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 38 studies involving 2,995 patients, non-pharmacological interventions were associated with reductions in cough severity and improvements in cough-related quality of life.
- Pulmonary rehabilitation showed a greater effect on cough severity than other non-pharmacological interventions, with additional improvements reported for expectoration, dyspnea, and general quality of life.
📋 Practice Implication: Pulmonary rehabilitation is a reasonable evidence-supported component of symptom management for lung-cancer-associated cough, alongside other non-drug approaches.
|
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026) - Systematic Review and Meta-Analysis
Key Findings
- Liquid-biopsy multimodal models achieved 90.2% sensitivity and 83.6% specificity for pulmonary-nodule assessment, compared with 81.5% and 67.9% for CT-based evaluation.
- Multimodal integration improved discrimination of malignant from benign nodules compared with CT-only and risk-prediction models.
📋 Practice Implication: For indeterminate pulmonary nodules, multimodal liquid-biopsy strategies may complement imaging and risk models, but their role should be confirmed within validated clinical pathways.
|
Frontiers in immunology (2026) - Systematic Review and Network Meta-Analysis
Key Findings
- Toripalimab plus chemotherapy had superior overall survival versus most other regimens in non-squamous NSCLC (hazard ratio range, 0.42-0.65) but inferior overall survival versus many comparators in squamous NSCLC (comparator-versus-toripalimab hazard ratio range, 0.47-0.65).
- In the PD-L1 <1% subgroup, nivolumab plus ipilimumab showed a trend toward better overall survival than pembrolizumab plus chemotherapy in squamous NSCLC (hazard ratio, 0.59), while pembrolizumab plus chemotherapy ranked highest for non-squamous NSCLC (SUCRA, 0.90).
📋 Practice Implication: First-line ICI selection in advanced NSCLC should account for histologic subtype in addition to PD-L1 status, because regimen performance was not uniform across squamous and non-squamous disease.
|
The Cochrane database of systematic reviews (2026) - Network Meta-Analysis
Key Findings
- PE plus benmelstobart plus anlotinib reduced the hazard of death versus PE alone (hazard ratio, 0.61; 95% CI, 0.47-0.79) and produced the largest reduction in progression hazard (hazard ratio, 0.32; 95% CI, 0.25-0.40).
- Safety varied by regimen: PE plus serplulimab increased any-adverse-event risk (risk ratio, 1.25; 95% CI, 1.08-1.43), while several combinations increased serious-adverse-event risk.
📋 Practice Implication: Comparative first-line decisions in extensive-stage SCLC should balance regimen-specific survival gains against differing serious and overall adverse-event risks rather than treating chemo-immunotherapy combinations as interchangeable.
|
Immunotherapy (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 12 trials involving 2,084 patients, chemotherapy plus anti-PD-(L)1 improved progression-free survival versus chemotherapy (hazard ratio, 0.68; 95% CI, 0.60-0.77) and overall survival (hazard ratio, 0.81; 95% CI, 0.70-0.94).
- The combination improved overall response rate (risk ratio, 1.61; 95% CI, 1.26-2.05) in advanced PD-L1-negative nonsquamous NSCLC.
📋 Practice Implication: These pooled data support chemo-immunotherapy as an evidence-based first-line option even when PD-L1 is negative, while subgroup-level data and heterogeneity warrant individualized interpretation.
|
|
💡
Summary
Recent evidence supports multimodal liquid-biopsy assessment for pulmonary nodules and histology-aware selection of first-line immunotherapy in advanced NSCLC. In SCLC, network evidence shows that survival benefits from first-line combinations vary alongside regimen-specific toxicity, while pulmonary rehabilitation and other non-pharmacological interventions can improve lung-cancer-associated cough and related symptoms.
|
|